Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has received a consensus rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $36.56.

A number of analysts recently commented on XNCR shares. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wells Fargo & Company started coverage on shares of Xencor in a report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 price objective on the stock. Royal Bank of Canada upped their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th.

Xencor Price Performance

Shares of XNCR stock opened at $20.05 on Thursday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $24.05 and a 200-day moving average price of $21.00. Xencor has a 52 week low of $15.31 and a 52 week high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm’s revenue was down 81.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) EPS. On average, sell-side analysts predict that Xencor will post -3.68 earnings per share for the current year.

Insider Transactions at Xencor

In related news, Director Alan Bruce Montgomery sold 1,421 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total value of $38,409.63. Following the completion of the transaction, the director now owns 9,140 shares of the company’s stock, valued at approximately $247,054.20. This represents a 13.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP John R. Desjarlais sold 68,684 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock valued at $3,277,609 over the last three months. Corporate insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XNCR. Rhumbline Advisers raised its position in shares of Xencor by 2.8% during the second quarter. Rhumbline Advisers now owns 154,573 shares of the biopharmaceutical company’s stock valued at $2,926,000 after buying an additional 4,265 shares during the last quarter. TD Asset Management Inc lifted its stake in Xencor by 1.5% in the 2nd quarter. TD Asset Management Inc now owns 145,650 shares of the biopharmaceutical company’s stock worth $2,757,000 after purchasing an additional 2,200 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of Xencor by 121.2% during the 2nd quarter. Quest Partners LLC now owns 18,639 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 10,214 shares during the last quarter. American Century Companies Inc. grew its position in shares of Xencor by 14.5% during the second quarter. American Century Companies Inc. now owns 95,375 shares of the biopharmaceutical company’s stock valued at $1,805,000 after purchasing an additional 12,083 shares in the last quarter. Finally, WINTON GROUP Ltd increased its holdings in shares of Xencor by 4.2% in the second quarter. WINTON GROUP Ltd now owns 46,481 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 1,883 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.